These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 28284212)

  • 1. Combination of glycopyrronium and indacaterol inhibits carbachol-induced ERK5 signal in fibrotic processes.
    Namba Y; Togo S; Tulafu M; Kadoya K; Nagahama KY; Taka H; Kaga N; Orimo A; Liu X; Takahashi K
    Respir Res; 2017 Mar; 18(1):46. PubMed ID: 28284212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Specific Features of Fibrotic Lung Fibroblasts Highly Sensitive to Fibrotic Processes Mediated via TGF-β-ERK5 Interaction.
    Kadoya K; Togo S; Tulafu M; Namba Y; Iwai M; Watanabe J; Okabe T; Jin J; Kodama Y; Kitamura H; Ogura T; Kitamura N; Ikeo K; Takeda T; Kondo N; Takahashi K
    Cell Physiol Biochem; 2019; 52(4):822-837. PubMed ID: 30946557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of roflumilast with a beta-2 adrenergic receptor agonist inhibits proinflammatory and profibrotic mediator release from human lung fibroblasts.
    Tannheimer SL; Wright CD; Salmon M
    Respir Res; 2012 Mar; 13(1):28. PubMed ID: 22452977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Computed tomography (CT)-assessed bronchodilation induced by inhaled indacaterol and glycopyrronium/indacaterol in COPD.
    Shimizu K; Seto R; Makita H; Suzuki M; Konno S; Ito YM; Kanda R; Ogawa E; Nakano Y; Nishimura M
    Respir Med; 2016 Oct; 119():70-77. PubMed ID: 27692151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination therapy with indacaterol and glycopyrronium bromide in the management of COPD: an update on the evidence for efficacy and safety.
    Ridolo E; Montagni M; Riario-Sforza GG; Baroni M; Incorvaia C
    Ther Adv Respir Dis; 2015 Apr; 9(2):49-55. PubMed ID: 25691493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Profile of inhaled glycopyrronium bromide as monotherapy and in fixed-dose combination with indacaterol maleate for the treatment of COPD.
    Prakash A; Babu KS; Morjaria JB
    Int J Chron Obstruct Pulmon Dis; 2015; 10():111-23. PubMed ID: 25609944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ERK5 inhibition ameliorates pulmonary fibrosis via regulating Smad3 acetylation.
    Kim S; Lim JH; Woo CH
    Am J Pathol; 2013 Dec; 183(6):1758-1768. PubMed ID: 24095924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of a fixed-dose combination of indacaterol and Glycopyrronium for the treatment of COPD: a systematic review.
    Rodrigo GJ; Plaza V
    Chest; 2014 Aug; 146(2):309-317. PubMed ID: 24556877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycopyrronium + indacaterol. A fixed-dose combination with no advantages in COPD.
    Prescrire Int; 2014 Dec; 23(155):288. PubMed ID: 25629143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The combination of indacaterol and glycopyrronium has effects on symptoms, lung function, and rate of exacerbations in COPD patients].
    Ulrik CS
    Ugeskr Laeger; 2014 Sep; 176(38):. PubMed ID: 25294211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetics of IND/GLY (indacaterol/glycopyrronium) in COPD patients.
    Demin I; Bartels C; Graham G; Bieth B; Gautier A; Tillmann HC; Sechaud R
    Int J Clin Pharmacol Ther; 2016 Jun; 54(6):405-15. PubMed ID: 27049057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of the LABA/LAMA dual bronchodilator indacaterol/glycopyrronium in a Swedish healthcare setting.
    Price D; Keininger D; Costa-Scharplatz M; Mezzi K; Dimova M; Asukai Y; Ställberg B
    Respir Med; 2014 Dec; 108(12):1786-93. PubMed ID: 25307414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of (a Combination of) the Beta
    Maarsingh H; Oldenburger A; Han B; Zuidhof AB; Elzinga CRS; Timens W; Meurs H; Sopi RB; Schmidt M
    Cells; 2021 May; 10(5):. PubMed ID: 34069899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Indacaterol/glycopyrronium bromide fixed-dose combination for the treatment of COPD.
    Schachter EN
    Drugs Today (Barc); 2013 Jul; 49(7):437-46. PubMed ID: 23914352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Indacaterol and glycopyrronium versus indacaterol on body plethysmography measurements in COPD-a randomised controlled study.
    Salomon J; Stolz D; Domenighetti G; Frey JG; Turk AJ; Azzola A; Sigrist T; Fitting JW; Schmidt U; Geiser T; Wild C; Kostikas K; Clemens A; Brutsche M
    Respir Res; 2017 Jan; 18(1):13. PubMed ID: 28077140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advances in COPD disease management with fixed-dose long-acting combination therapies.
    Bateman ED; Mahler DA; Vogelmeier CF; Wedzicha JA; Patalano F; Banerji D
    Expert Rev Respir Med; 2014 Jun; 8(3):357-79. PubMed ID: 24802656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological characterisation of the interaction between glycopyrronium bromide and indacaterol fumarate in human isolated bronchi, small airways and bronchial epithelial cells.
    Cazzola M; Calzetta L; Puxeddu E; Ora J; Facciolo F; Rogliani P; Matera MG
    Respir Res; 2016 Jun; 17(1):70. PubMed ID: 27296533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD.
    Zhong N; Wang C; Zhou X; Zhang N; Humphries M; Wang L; Thach C; Patalano F; Banerji D;
    Int J Chron Obstruct Pulmon Dis; 2015; 10():1015-26. PubMed ID: 26082625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of combined indacaterol and glycopyrronium bromide (QVA149) for the treatment of COPD in Japan.
    Horita N; Kaneko T
    Int J Chron Obstruct Pulmon Dis; 2015; 10():813-22. PubMed ID: 25960646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term safety of glycopyrrolate: A randomized study in patients with moderate-to-severe COPD (GEM3).
    Mahler DA; Gifford AH; Satti A; Jessop N; Eckert JH; D'Andrea P; Mota F; Banerjee R
    Respir Med; 2016 Jun; 115():39-45. PubMed ID: 27215502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.